Entity

Time filter

Source Type

San Diego, CA, United States

Patent
AnaptysBio | Date: 2011-08-02

The disclosure relates to an isolated IL-17-binding agent which comprises an immunoglobulin heavy chain polypeptide comprising SEQ ID NO: 1 and optionally an immunoglobulin light chain polypeptide comprising SEQ ID NO: 23, except that one or more specific of residues of SEQ ID NO: 1 and SEQ ID NO: 23 are replaced with a different residue. The disclosure also provides vectors, compositions, and methods of using the IL-17-binding agent to treat an IL-17-mediated disease.


Patent
AnaptysBio | Date: 2014-05-02

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease.


The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to complement protein C5. The invention provides a C5-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention provides an isolated complement protein C5 epitope. The invention also provides related vectors, compositions, and methods of using the C5-binding agent to treat an C5-mediated disease.


Patent
AnaptysBio | Date: 2013-09-19

The invention provides isolated amino acid sequences comprising the framework regions of an immunoglobulin heavy chain or light chain polypeptide, wherein certain amino acid residues of the framework regions are replaced with different amino acid residues that confer increased thermostability in vitro or in vivo. The invention also provides an isolated amino acid sequence of the constant region of an immunoglobulin heavy chain polypeptide wherein certain amino acid residues of the constant region are replaced with different amino acid residues that confer increased thermostability in vitro or in vivo.


Patent
AnaptysBio | Date: 2012-10-24

The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.

Discover hidden collaborations